Research
Hormonal
Intermittent Fasting improves metabolic health markers, including insulin sensitivity, lipid profiles (reduced triglycerides and LDL), and blood pressure, independent of weight loss magnitude, through mechanisms involving ketone body production and hormonal regulation.
Beyond weight loss, IER can improve your blood lipids and blood pressure. This happens partly because your body switches to burning fat for fuel (ketones) during fasting periods, which improves insulin sensitivity and reduces inflammation. You do not need to lose a massive amount of weight to see these metabolic benefits.
GoodSupportsHIGH confidence
Fasting induces the expenditure of glucose... along with a change in energy intake from glucose metabolism to fat-derived ketone bodies... Ketone bodies... improve glucose regulation with abdominal fat loss and regulate cardiological parameters such as blood pressure and heart rate.
Why this rating
Supported by multiple RCTs and meta-analyses cited in the review.
Source
The Role of Intermittent Energy Restriction Diet on Metabolic Profile and Weight Loss among Obese Adults
Agata Stanek et al. · Nutrients · 2022
DOI 10.3390/nu14071509
narrative_reviewCited 37×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intermittent Energy Restriction (IER) diets, including Alternate-Day Fasting (ADF) and Time-Restricted Feeding (TRF), produce weight loss and metabolic improvements (reduced triglycerides, LDL, and blood pressure) that are comparable to Continuous Energy Restriction (CER) diets when total caloric intake is matched.Good
- Adherence to Time-Restricted Feeding (TRF) is generally high and well-tolerated, with compliance rates of 65-75% in short-term studies, and greater fasting duration is associated with higher adherence.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →